Loading organizations...
§ Public · Menlo Park, CA, USA
A clinical-stage biopharmaceutical company developing small molecule therapeutics for rare and chronic infectious diseases.
Founded in 2017 by Eric Easom, Joseph Zakrzewski, George Talbot, and Michael Alley, AN2 Therapeutics is a Menlo Park-based clinical-stage biopharmaceutical company developing small molecule therapeutics for rare and serious infectious diseases using a boron chemistry platform. The publicly traded firm focused on epetraborole, an oral treatment for non-tuberculous mycobacterial lung disease, before discontinuing Phase 3 development in 2024 to undergo strategic restructuring. Operating with 21 employees, the enterprise maintains a $30.61 million market capitalization following its $69 million initial public offering in 2022 and an $80 million Series B round. The company receives financial and grant support from notable organizations, including RA Capital Management, BVF Partners, Mountain Group Partners, and the Bill and Melinda Gates Foundation. Beyond its lead candidate, the biotech targets global health initiatives and diseases like Chagas disease and acute melioidosis.
AN2 Therapeutics has raised $92.0M across 2 funding rounds.
AN2 Therapeutics has raised $92.0M in total across 2 funding rounds.
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics based on boron chemistry to treat rare, chronic, and serious infectious diseases with high unmet needs, such as Chagas disease, melioidosis, and NTM lung disease caused by *M. abscessus*, alongside oncology targets.[1][2][3] Its lead candidate, AN2-502998, targets chronic Chagas disease—a parasitic infection affecting 6-7 million people worldwide, including 300,000 in the U.S.—by offering potential curative activity in preclinical models across species, including non-human primates, where current treatments like benznidazole and nifurtimox fail due to poor efficacy and side effects in the chronic phase.[3][4] AN2 serves patients in global health settings, particularly neglected tropical diseases, partnering with organizations like DNDi to accelerate development; it has initiated a Phase 1 trial for AN2-502998, expecting completion in H2 2025 and Phase 2 in 2026, demonstrating early clinical momentum.[3][4]
AN2 Therapeutics emerged from the legacy of Anacor's Neglected Diseases team, which raised over $80 million and discovered over a dozen compounds for diseases like malaria, tuberculosis, Chagas, African sleeping sickness, and leishmaniasis.[1] Co-founder Eric Easom, Chairman, President, and CEO, led that team and chaired the Infectious Disease Research Institute board from 2009-2013, bringing deep expertise in boron-based drug discovery.[1][3] The company's lead asset, AN2-502998 (formerly AN15368), originated at Anacor in collaboration with the University of Georgia and Wellcome funding, marking a pivotal moment in advancing boron chemistry from neglected diseases research to a focused pipeline.[4] This backstory reflects a shift from broad philanthropic discovery to a commercial biopharma entity committed to high-impact therapies.[1][2]
AN2 rides the wave of advances in neglected tropical disease (NTD) therapeutics, where climate change, migration, and diagnostics improvements are expanding awareness and urgency for treatments like those for Chagas—a vector-borne parasite disease increasingly relevant in non-endemic regions like the U.S. and Europe.[3][4] Timing aligns with post-pandemic focus on antimicrobial resistance and rare infections, bolstered by nonprofit-public partnerships (e.g., DNDi, Wellcome) that de-risk development for pharma.[1][3] Market forces favor boron-based innovation, as traditional antibiotics fail chronic phases of diseases like Chagas, creating opportunities for first-in-class cures amid a 50-year treatment drought.[4] AN2 influences the ecosystem by validating boron chemistry for NTDs and oncology, potentially inspiring spinouts in crop protection and animal health while accelerating access via collaborations.[1][3]
AN2 is poised for inflection with Phase 1 readout of AN2-502998 in H2 2025 and Phase 2 proof-of-concept in 2026, potentially validating its platform and attracting partnerships or funding amid rising NTD investment.[3][4] Trends like AI-driven discovery, climate-impacted infectious diseases, and gender-equitable R&D (per DNDi priorities) will shape its path, expanding boron applications to oncology and new indications.[1][3] Its influence may grow by bridging pharma and global health nonprofits, delivering cures that transform outcomes for millions—echoing its Anacor roots in high-unmet-need innovation.[1][2]
AN2 Therapeutics has raised $92.0M across 2 funding rounds. Most recently, it raised $80.0M Series B in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 7, 2022 | $80M Series B | RA Capital Management | Avidity Partners, BVF Partners, Hatteras Venture Partners, Monashee Investment Management, Surveyor Capital | Announced |
| Nov 1, 2019 | $12M Series A | Mountain Group Partners | Adjuvant Capital, Biorock Ventures, Brii Biosciences | Announced |
AN2 Therapeutics has raised $92.0M in total across 2 funding rounds.
AN2 Therapeutics's investors include RA Capital Management, Avidity Partners, BVF Partners, Hatteras Venture Partners, Monashee Investment Management, Surveyor Capital, Mountain Group Partners, Adjuvant Capital, BioRock Ventures, Brii Biosciences.